Table 3. Study characteristics of studies included in meta-analysis (n = 16): regimens, population size, timepoint of analysis and virological outcome data are enlisted.
| INI (n = ) | CTR (n = ) | Regimen | Analysis time point (w) | |
| ART-naive patients | ||||
| STARTMRK [16] | 281 | 282 | RAL 400 mg bd + TDF/FTC vs. EFV + TDF/FTC | 48 |
| Protocol 004 [21] | 160 | 38 | RAL 100, 200, 400 or 600 mg bd + TDF/3TC vs. EFV + TDF/3TC | 48 |
| GS-236-014 [26] | 48 | 23 | EVG/COBI single tablet qd+ TDF/FTC vs. EFV + TDF/FTC | 48 |
| GS-236-0102 [25] | 348 | 352 | EVG/COBI/FTC/TDF qd vs EFV/TDF/FTC | 48 |
| SPRING-1 [28] | 155 | 50 | DTG 10,25 or 50 mg + TDF/FTC or ABC/3TC vs. EFV + TDF/FTC or ABC/3TC | 48 |
| SINGLE [14] | 414 | 419 | DTG 50 mg + ABC/3TC vs. EFV/TDF/FTC | 48 |
| GS-236-0103 [31] | 353 | 355 | EVG/COBI/FTC/TDF qd vs ATV/r + TDF/FTC | 48 |
| SPARTAN [13] | 63 | 31 | RAL 400 mg bd + ATV vs. ATV/r + TDF/FTC | 24 |
| PROGRESS [32] | 101 | 105 | RAL 400 mg bd + LPV/r vs. LPV/r + TDF/FTC | 24 |
| RADAR [33] | 40 | 40 | RAL 400 mg bd + DRV/r vs. DRV/r + TDF/FTC | 24 |
| ART-experienced patients with virological failure | ||||
| BENCHMRK 1 and 2 [2] | 461 | 237 | RAL 400 mg bd + NNRTI + NRTI vs. Placebo + NNRTI + NRTI | 24 |
| Protocol 005 [36], [37] | 134 | 45 | RAL 200, 400 or 600 mg bd + optimized BR vs. placebo + optimized BR | 24 |
| GS-183-105 [38] | 205 | 73 | EVG/RIT 20, 50 or 125 mg bd + optimized BR vs. PI/r + optimized BR | 24 |
| ART-experienced patients switching suppressive therapy | ||||
| SWITCHMRK 1 and 2 [48] | 353 | 354 | RAL 400 mg bd + BR − LPV/r vs. BR | 24 |
| SPIRAL [49] | 139 | 134 | RAL 400 mg bd + BR − PI/r vs. BR | 32 |
| EASIER ANRS 138 [50] | 85 | 85 | RAL 400 mg bd + BR − T20 vs. BR +− T20 or RAL (>24w) | 24 |
INI-containing treatment arm is underlined.
ART = antiretroviral treatment; INI = integrase inhibitor; CTR = control arm; VL<50 = viral load or HIV RNA <50 copies/ml; RAL = raltegravir; EFV = efavirenz; EVG = elvitegravir; COBI = cobicistat; DTG = dolutegravir; ATV = atazanavir; DRV = darunavir; TDF/FTC = tenofovir/emtricitabine; ABC/3TC = abacavir/lamivudine; LPV = lopinavir; r = ritonavir; (N)NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; BR = background regimen; T20 = enfurvirtide.